An epidemiological survey to assess the clinical use of cephalosporins in community-acquired respiratory tract infections
Keywords:Cephalosporins, Fluoroquinolones, Respiratory tract infections
Background: In outpatient management of respiratory tract infections, the clinicians’ preferences always have a broad spectrum of antibiotics as an empirical therapy. Clinical use of cephalosporins and fluoroquinolones has been recommended by various international guidelines as a monotherapy or as combination therapy to manage these. This survey was conducted to assess the in-clinic use and preference of cephalosporins or fluoroquinolones as monotherapy or as combination therapy in managing respiratory tract infections by Indian doctors.
Methods: A survey questionnaire was drafted to capture the feedback from cross-specialty regarding the preference of using antibiotics in respiratory tract infection in real time clinical settings.
Results: Data from 163 physicians were collected and evaluated across India. 79 (48%) clinicians reported pharyngitis/tonsillitis to be the most commonly encountered respiratory tract infection followed by community-acquired pneumonia (CAP) 62 (38%). 100 (61%) clinicians preferred use of cefpodoxime monotherapy as a primary line of treatment for the management of respiratory pharyngitis/tonsillitis. Use of short course therapy (≤1 week) of cefpodoxime and levofloxacin as combination therapy is preferred by 94 (58%) clinicians, in cases of acute exacerbation of chronic bronchitis (AECB) 85 (52%), and CAP 83 (51%). The clinical preference of levofloxacin was observed with only 16 (10%) clinicians, in lower respiratory tract infections, i.e. AECB and CAP.
Conclusion: In-clinic use of cefpodoxime as monotherapy is preferred in upper respiratory tract infections. However, clinicians recommend a combination therapy of cefpodoxime and levofloxacin in lower respiratory tract infections.
S KI, Chandy SJ, Jeyaseelan L, Kumar R, Suresh S. Antimicrobial prescription patterns for common acute infections in some rural and urban health facilities of India. Indian J Med Res. 2008;128(2):165-71.
Linder JA, Bates DW, Lee GM, Finkelstein JA. Antibiotic treatment of children with sore throat. JAMA. 2005;294(18):2315-22.
Chow AW, Benninger MS, Brook I, Brozek JL, Goldstein EJ, Hicks LA, et al. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis. 2012;54(8):e72-e112.
Wong DM, Blumberg DA, Lowe LG. Guidelines for the use of antibiotics in acute upper respiratory tract infections. Am Fam Physician. 2006;74(6):956-66.
Global Strategy for Asthma Management and Prevention. National Institutes of Health: National Heart, Lung, and Blood Institute. Washington, D.C: Bethesda, MD: National Institutes of Health; 2014.
Osih RB, McGregor JC, Rich SE, Moore AC, Furuno JP, Perencevich EN, et al. Impact of empiric antibiotic therapy on outcomes in patients with Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother. 2007;51(3):839-44.
Srishyla MV, Rani MA, Venkataraman BV. Drug utilization of antimicrobials in the in-patient setting of a tertiary hospital. Indian J Pharmacol. 1994;26:282-7.
Badar VA, Navale SB. Study of prescribing pattern of antimicrobial agents in medicine intensive care unit of a teaching hospital in Central India. J Assoc Physicians India. 2012;60:20-3.
White AR, Kaye C, Poupard J, Pypstra R, Woodnutt G, Wynne B. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. J Antimicrob Chemother. 2004;53 Suppl 1:i3-20.
Schreiner A. Beta-lactam antibiotics in lower respiratory tract infections. Scand J Infect Dis Suppl. 1984;42:129-34.
Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005;18(4):657-86.
Drawz SM, Bonomo RA. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev. 2010;23(1):160-201.
Ritrovato CA, Deeter RG. Respiratory tract penetration of quinolone antimicrobials: a case in study. Pharmacotherapy. 1991;11(1):38-49.
Cazzola M, Blasi F, Terzano C, Matera MG, Marsico SA. Delivering antibacterials to the lungs: considerations for optimizing outcomes. Am J Respir Med. 2002;1(4):261-72.
Grossman RF. The role of fluoroquinolones in respiratory tract infections. J Antimicrob Chemother. 1997;40 Suppl A:59-62.
Wierzbowski AK, Hoban DJ, Hisanaga T, DeCorby M, Zhanel GG. The use of macrolides in treatment of upper respiratory tract infections. Curr Allergy Asthma Rep. 2006;6(2):171-81.
Min JY, Jang YJ. Macrolide therapy in respiratory viral infections. Mediators Inflamm. 2012;2012:649570.
Ortqvist A. Treatment of community-acquired lower respiratory tract infections in adults. Eur Respir J Suppl. 2002;36:40s-53.
Portier H, Chavanet P, Gouyon JB, Guetat F. Five day treatment of pharyngotonsillitis with cefpodoxime proxetil. J Antimicrob Chemother. 1990;26 Suppl E:79-85.
Portier H, Chavanet P, Ichou F, The Multicentre Group. Five day antibiotherapy in presumed bacterial acute tonsillitis: a comparative study of cefpodoxime proxetil vs cefuroxime axetil. Poster presented at the International Congress of Infectious Disease, Montreal, July 15-19, 1990.
Kline NE, Kline MW. Cefpodoxime proxetil versus penicillin V in the treatment of streptococcal pharyngitis in children. Curr Ther Res. 1991;49:807-13.